Galapagos CSO hits the exit as the biotech looks to pick up the pieces after FDA's filgotinib rejection

Josh Sullivan

Months after Galapagos cut away broad swaths of its pipeline following a rejection for Gilead-partnered rheumatoid arthritis drug filgotinib, the biotech will now say goodbye to its longtime chief scientific officer as it considers its options moving ahead.

Piet Wigerinck will step down from his role later this year, the company announced on Tuesday. Wigerinck joined in 2008 as the SVP of development, and became the CSO in 2012. He oversaw the discovery of novel targets through to clinical proof-of-concept studies, led the first clinical research in healthy volunteers and was responsible for two Phase II programs for filgotinib, a JAK inhibitor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Galapagos CSO hits the exit as the biotech looks to pick up the pieces after FDA's filgotinib rejection

Josh Sullivan

Unlock this article instantly by becoming a free subscriber.

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Gala­pa­gos CSO hits the ex­it as the biotech looks to pick up the pieces af­ter FDA's fil­go­tinib re­jec­tion

Josh Sullivan

Unlock this article instantly by becoming a free subscriber.

more like this

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

His­to­gen files for bank­rupt­cy; Barinthus Bio shares Ph1b/2 da­ta for HPV treat­ment

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Galapagos CSO hits the exit as the biotech looks to pick up the pieces after FDA's filgotinib rejection

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment

CSL Vifor proposes a marketing campaign to settle European Commission investigation